Cellectar Biosci stock hits 52-week low at 1.38 - Investing.com
| CLRB Stock | USD 0.28 0.02 7.69% |
About 55% of Cellectar Biosciences' investors are presently thinking to get in. The analysis of overall sentiment of trading Cellectar Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Cellectar Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Cellectar Biosciences stock news signals to limit their universe of possible portfolio assets.
Cellectar |
Cellectar Biosci stock hits 52-week low at 1.38 Investing.com
Read at news.google.com
 |
Cellectar Biosciences Fundamental Analysis
We analyze Cellectar Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Cellectar Biosciences is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Cellectar Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectar Biosciences stock to make a market-neutral strategy. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics with similar companies.
Peers
Cellectar Biosciences Related Equities
| BPTH | Bio Path | 6.85 | ||||
| TENX | Tenax Therapeutics | 6.32 | ||||
| PULM | Pulmatrix | 2.57 | ||||
| BOLT | Bolt Biotherapeutics | 2.04 | ||||
| NXTC | NextCure | 1.25 | ||||
| BNTC | Benitec Biopharma | 2.30 | ||||
| MNPR | Monopar Therapeutics | 3.40 | ||||
| CAPR | Capricor Therapeutics | 4.91 |
Complementary Tools for Cellectar Stock analysis
When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |